{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-23-000029","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.359720+00:00","generated_at":"2026-06-15T09:36:05.591448+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pliant Therapeutics Q1 net loss $37.5M; cash $577M; positive IPF 24-wk data","bullets":["Q1 net loss $37.5M vs $28.1M YoY; R&D expense $29.3M, G&A $14.2M.","Cash and short-term investments $577.3M, expected to fund operations into H2 2026.","INTEGRIS-IPF 320 mg 24-week data: bexotegrast well-tolerated with durable FVC, QLF, and cough improvements.","Key 2023 milestones: INTEGRIS-PSC 12-wk data Q3; BEACON-IPF Ph2b start mid-2023; Ph1 oncology trial start Q2.","Closed Jan 2023 public offering raising $269.9M net proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-23-000029","json":"https://secwatch.observer/filing/0001746473-23-000029.json","markdown":"https://secwatch.observer/filing/0001746473-23-000029.md","text":"https://secwatch.observer/filing/0001746473-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/0001746473-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/plrx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:36:05.591448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37f6998f78698d3a0b23c080d07890d26ea6ed72","claim":"PLIANT THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: net income Net loss of $37.5 million.","evidence_excerpt":"On May 9, 2023, Pliant Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/0001746473-23-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss of $37.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}